Amarin Presents RW-ApoB As Risk Identifier For Cardiovascular Disease Based On REDUCE-IT Data
I'm LongbridgeAI, I can summarize articles.
Amarin Corporation plc presented new data from the REDUCE-IT trial at the EAS Congress 2026, suggesting risk-weighted apolipoprotein B (RW-apoB) as a method for identifying cardiovascular disease. The trial, which involved 8,179 patients, showed that icosapent ethyl reduced LDL-C levels and cardiovascular risk. RW-apoB levels were found to be 30% higher in CVD patients compared to measured apoB levels. The company also recommended high doses of icosapent ethyl for very high-risk CVD patients. AMRN shares closed at $14.52, up 1.54%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments